Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions (BIOFLEX-COF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03097679
Recruitment Status : Active, not recruiting
First Posted : March 31, 2017
Last Update Posted : February 20, 2020
Sponsor:
Information provided by (Responsible Party):
Alexander Wressnegger, Medical University of Vienna

Brief Summary:

The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal hyperplasia at one and two years after implantation of nitinol-stents with high vs. low COF in de-novo femoropopliteal occlusive lesions in patients with symptomatic peripheral arterial disease.

The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar).


Condition or disease Intervention/treatment Phase
Stent Restenosis Intimal Hyperplasia Device: Pulsar Stent Device: LifeStent Flexstar Vascular Stent Not Applicable

Detailed Description:

Self-expanding nitinol stents must be oversized at least by a minimal amount to ensure contact with the vessel wall and prevent migration. Once the stent is deployed it exerts a continuous force upon the vascular wall, termed chronic outward force (COF). Data about COF and neointimal hyperplasia in humans are currently lacking. Some animal studies, though, found a markedly increased neointimal hyperplasia in stents with high oversizing and thus high COF. The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal hyperplasia at one and two years after implantation of nitinol-stents with high vs. low COF in de-novo femoropopliteal occlusive lesions in patients with symptomatic peripheral arterial disease.

The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar). Diameter of implanted stents will be measured at every two millimetres along the stent axis on DICOM images of the respective completion angiography using image processing software.

The scheduled time for recruitment is 2 years. There will be two follow-up evaluations at 12 and 24 months.

Primary endpoint is the amount of in-stent neointima at one year, assessed by contrast-enhanced CT angiography (CTA). Secondary objectives are the amount of in-stent neointima at two years, device- and procedure-related adverse events and target lesion revascularisation (TLR) rate.

In the control examinations stent diameter and true lumen diameter will be measured on DICOM images every two millimetres along the stent axis to quantify the relative amount of in-stent restenosis.

The present study is challenging in that it compares two different self-expanding nitinol-stents head-to-head against each other. To optimize the power of this study, both clinical TLR and binary re-stenosis at Colour flow Doppler Ultrasound were dropped as primary endpoints. Instead the amount of neointima inside the stent accessed by CTA was selected as outcome parameter.

The study differs further from similar previous trials in its generous inclusions criteria. This was done in effort to perform the trial on a patient sample that closely represents real-world patients of a specialised endovascular centre.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions
Actual Study Start Date : October 1, 2015
Actual Primary Completion Date : July 31, 2019
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Active Comparator: low COF-group
The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
Device: Pulsar Stent
Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.

Active Comparator: high COF-group
The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
Device: LifeStent Flexstar Vascular Stent
Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.




Primary Outcome Measures :
  1. Amount of in-stent restenosis [ Time Frame: one and two years post-procedure ]
    Mean amount of in-stent restenosis in percent along the stent axis at one and two years post-procedure.


Secondary Outcome Measures :
  1. Adverse Events ISO 14155:2011 [ Time Frame: within two years post-procedure ]
    Adverse Events ISO 14155:2011

  2. Target lesion revascularisation (TLR) [ Time Frame: within two years post-procedure ]
    In patients with TLR the amount of in-stent restenosis will be assessed at the time of TLR.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patient related:

  1. Subject (or their legal guardian) has read, understood and provided written informed consent, which has been reviewed and approved by the Institutional Review Board.
  2. At least 18 years of age.
  3. Male, infertile female or female participants of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure.
  4. Projected life expectancy of greater than two years.
  5. The ability to comply with protocol follow-up requirements and required testing.

Clinical:

  1. Lifestyle-limiting claudication or CLI (meeting angiographic entry criteria) affecting a lower extremity (Rutherford stages 2-5). Patients with Rutherford stage 2 are only eligible after unsuccessful conventional and/or medicamentous therapy.
  2. Resting ankle-brachial index (ABI) ≤ 0.8 in the study limb.
  3. Inflow lesion - if present - has been treated successfully (inflow treatment in same procedure permissible)

Angiographic and Lesion Requirements (assessed intraoperatively):

  1. TASC A-D lesions from stenoses /occlusions ≤ 35cm.
  2. Popliteal artery is patent 5 cm proximal to the radiographic knee joint line.
  3. Reference diameter of 4.0 - 7.0 mm in proximal and distal treatment segments within the SFA.
  4. Patent SFA orifice (the proximal 5 mm after femoral bifurcation).
  5. At least one patent (<50% stenotic) inflow vessel present, proven angiographically. Study eligibility is given when inflow lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as <50% stenosis without death or severe vascular complication.
  6. At least one patent (<50% stenotic)tibial artery runoff to the ankle present, proven angiographically. Study eligibility is given when runoff vessel lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as <50% stenosis without death or severe vascular complication.Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel.

Exclusion Criteria:

  1. Pregnant and/or breast-feeding women.
  2. Lesion length > 35 cm.
  3. Flow-limiting occlusive disease of inflow and / or outflow arteries that cannot be treated sufficiently.
  4. Previous stenting or femoral bypass surgery in the target vessel.
  5. Clinical relevant aneurysmatic disease of the abdominal aorta, ipsilateral femoral arteries or arteries of the knee.
  6. Rutherford stage 0, 1 or 6
  7. Non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis).
  8. Septicaemia.
  9. Ischemic stroke within the last three months.
  10. Any previously known coagulation disorder, including hypercoagulability
  11. Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion).
  12. Contraindication to anticoagulation or antiplatelet therapy.
  13. Known allergy to medication or contrast media used in this trial, if pre-treatment is not possible (physician's discretion).
  14. Known allergies to stent components (especially Nickel).
  15. Severe calcification of the target lesion.
  16. Current participation in another clinical research trial, that has not reached its primary endpoint.
  17. The patient is institutionalized based on a legal verdict.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03097679


Locations
Layout table for location information
Austria
Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alexander Wressnegger, Dr.med.univ., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT03097679    
Other Study ID Numbers: 1026/2015
First Posted: March 31, 2017    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperplasia
Pathologic Processes